Chemoimmune Prophylaxis of Superficial Bladder Cancer

Abstract

Chemoimmune prophylaxis with i.v. cyclophosphamide and intravesical and systemic BCG treatment was begun after complete tumor resection in 90 patients with superficial urothelial bladder cancer. Compared to a historical patient control group treated by tumor resection alone, a distinct decrease in the recurrence rate was noted in the immune treated group which was most marked during the 1st 12 mo. postoperatively. The side effects of this treatment were tolerable. These results are discussed with regard to the reported findings in the literature. Possible immune biological mechanisms of the tumor protection achieved by cyclophosphamide and BCG are suggested.